Dexcom, Inc. CEO Net Worth

Last Updated Mar 10, 2025
CEO NameKevin Sayer
NationalityUnited States
Net Worth Estimation$70 million

Kevin Sayer's estimated net worth of around $70 million is primarily attributed to his executive compensation, significant stock ownership, and long tenure as CEO and Chairman of Dexcom, Inc., a leader in continuous glucose monitoring technology. The valuation reflects cumulative stock awards, equity appreciation, bonuses, and other financial incentives tied to Dexcom's substantial market growth.

Kevin Sayer, CEO of Dexcom, Inc. in the healthcare category, has an estimated net worth of $70,000,000. This places his net worth at approximately 78% of the maximum estimated CEO net worth and 700% of the minimum.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Kevin Sayer Performance in Dexcom, Inc.

Kevin Sayer, CEO of Dexcom, Inc., demonstrates visionary leadership and data-driven decision-making that have driven the company's innovation in continuous glucose monitoring technology. Under his guidance, Dexcom has significantly expanded its market presence and revenue, positioning the firm as a leader in diabetes care solutions. Sayer's strategic emphasis on product development and global partnerships has markedly improved overall company performance and shareholder value.


Latest News

Dexcom CEO Kevin Sayer to Step Down, Jake Leach to Succeed in 2026

Kevin Sayer, CEO of Dexcom since 2015, will step down at the start of 2026, transitioning to executive chairman; Jake Leach, COO and president with 21 years at Dexcom, will become CEO amid strong company growth and increasing competition. Sayer recently took a temporary medical leave, with Leach serving as interim while Sayer praised Leach as the right leader for the future. Dexcom reported $1.198 billion in Q3 2025 revenue and is launching new technology to expand glucose sensing access.
Source: http://www.medtechdive.com/news/dexcom-ceo-change-kevin-sayer-jake-leach/756382/



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Dexcom, Inc. are subject to change from time to time.

Comments

No comment yet